Year: 2023
Type: dissertation
Study design: Observational Study
Abstract: Background Searching for reliable diagnostic tumor markers is essential to improve cancer management. This study evaluated two different potential candidates involved in tumor development and progression of colon carcinoma, the macrophage marker CD68 and the epigenetic marker DNMT3B. Tumor-associated macrophages take a controversial role in the tumor microenvironment as both pro- and anti-tumoral effects have been described. Yet in colon carcinoma, contrary to many other tumor entities, most reports state that a dense macrophage infiltration is associated with favorable prognosis. DNA-Methyltransferases though are referred to provide an oncogenic behavior and to participate in carcinogenesis. DNMT3B in particular is reportedly highly expressed and correlated to epigenetic gene silencing and tumor aggressiveness in several cancer types, including colon cancer. This investigation tried to answer the questions if CD68 and DNMT3B are suitable diagnostic tumor markers, if they are helpful in prediction of aggressiveness and if they are of prognostic relevance. Materials and methods This retrospective histopathological study had available a colon carcinoma patient cohort, that underwent surgical resection at the university hospital Erlangen, Germany. The expression of CD68+ macrophages and DNMT3B was investigated using immunohistochemical staining analysis on multiple specimen replicates collected in tissue microarrays. The quantity of CD68+ tumor associated macrophages was assessed in 123 patients, the expression intensity of DNMT3B in 144 patients respectively. Central interests to figure out have been the spatial distribution, comparing tumor center to invasive front, as well as the relationship to patients' clinico-pathological parameters and their clinical outcomes. Then both markers were correlated to each other on 110 patients. Results Advanced clinical stages showed a significantly decreased CD68+ macrophage infiltration at the invasive front (UICC IF: p=0.016). CD68+ macrophage counts at the invasive front especially negatively correlated with N-status (IF: p=0.006). High DNMT3B levels were significantly associated with rising malignancy. DNMT3B displayed a strong correlation to tumor grade (TC: p=0.000), T-status (IF: p=0.005) and M-status (TC: p=0.022; IF: p=0.034). Concerning survival, increased DNMT3B showed a slightly negative influence on prognosis (p=0.152). Both expressions of CD68 and DNMT3B increased significantly in parallel from tumor center towards invasive front (p<0.001). Yet CD68 and DNMT3B did not show a direct impact on each other. Conclusion This study has given additional indices that in colon cancer DNMT3B is driving tumor progression, growth and metastasis, while CD68+ tumor-associated macrophages are exhibiting a protective role against tumor spread. Both markers display promising characteristics; further intense research will show if they might be implemented as additional diagnostic value into clinical routine in future and if their specific targeting might serve as basis for the development of a new anti-cancer treatment generation.
Author: Köhler, Juliane
Institution: Friedrich-Alexander-Universität Erlangen-Nürnberg
Language: English
Topic: Immune cells in cancer
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: colon cancer, CD68+ macrophages, tumor-associated macrophages, DNMT3B, DNA methyltransferases, prognostic factors, tumor microenvironment, tumor aggressiveness, tumor grade, lymph node metastasis, tumor stage, survival, epigenetic silencing, invasion front, tumor center, colon cancer progression, DNA methylation
Open Access status: green
OpenAlex ID: W7024605886
